Wuhan Healthgen Biotechnology Corp. (SHA:688765)

Market Cap	26.23B
Revenue (ttm)	23.39M +17.0%
Net Income	-160.81M
EPS	-0.59
Shares Out	357.50M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	915,287
Average Volume	1,560,092
Open	74.13
Previous Close	73.89
Day's Range	73.27 - 74.13
52-Week Range	68.68 - 132.03
Beta	n/a
RSI	44.17
Earnings Date	Apr 17, 2026

About SHA:688765

Wuhan Healthgen Biotechnology Corp. engages in the research and development of molecular pharmaceuticals in China. The company offers recombinant human serum albumin, proteins for cosmetics ingredients, and other recombinant proteins. It also provides recombinant growth factors, such as recombinant human epidermal growth factor, recombinant human basic fibroblast growth factor, recombinant human insulin-like growth factor-1 LR3, recombinant human vascular endothelial growth factor, recombinant human keratinocyte growth factor, recombinant human...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2006
• Employees: 155
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688765

Financial Performance

In 2024, SHA:688765's revenue was 25.22 million, an increase of 3.92% compared to the previous year's 24.26 million. Losses were -151.37 million, -19.04% less than in 2023.